OptimizeRx(OPRX)

Search documents
OptimizeRx (OPRX) Investor Presentation - Slideshow
2022-09-15 17:48
Technology Solutions For Life Sciences at the Point-of-Care Corporate Presentation Physician Awareness Digital Therapy Initiation Patient Adherence Our Mission At OptimizeRx ― we are building a more informed and empowered healthcare community by developing new technology solutions that help people start and stay on life-impacting therapies. Growth Leaders | Growth Drivers | --- | --- | --- | --- | --- | --- | --- | |-------|--------------------------------------------------|-------|-------|----------------- ...
OptimizeRx(OPRX) - 2022 Q2 - Earnings Call Transcript
2022-08-10 01:50
OptimizeRx Corporation (NASDAQ:OPRX) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants William Febbo - CEO and Director Ed Stelmakh - CFO and COO Stephen Silvestro - Chief Commercial Officer Conference Call Participants Ryan Daniels - William Blair Joy Zhang - SVB Securities Sean Dodge - RBC Capital Markets Eric Martinuzzi - Lake Street Marc Wiesenberger - B. Riley Securities Jeff Garro - Piper Sandler Operator Good afternoon, everyone. Thank you for joining OptimizeRx's Second ...
OptimizeRx(OPRX) - 2022 Q2 - Quarterly Report
2022-08-09 21:23
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction ...
OptimizeRx (OPRX) Investor Presentation - Slideshow
2022-06-26 11:04
OptimizeRx Technology Solutions For Life Sciences at the Point-of-Care Corporate Presentation Physician Awareness Digital Therapy Initiation Patient Adherence Our Mission At OptimizeRx ― we are building a more informed and empowered healthcare community by developing new technology solutions that help people start and stay on life-impacting therapies. Growth Leaders | Growth Drivers EXPERIENCE 20+ Leading Health Services and Financial Businesses `) Med Panel Will Febbo Chief Executive Officer Ed Stelmakh Ch ...
OptimizeRx(OPRX) - 2022 Q1 - Quarterly Report
2022-05-09 20:46
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdictio ...
OptimizeRx(OPRX) - 2022 Q1 - Earnings Call Transcript
2022-05-05 02:42
OptimizeRx Corporation (NASDAQ:OPRX) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Ed Stelmakh - Chief Financial Officer & Chief Operating Officer Andrew D’Silva - Senior Vice President of Corporate Finance Conference Call Participants Ryan Daniels - William Blair Sean Dodge - RBC Capital Markets Mark Wiesenberger - B. Riley Securities Max Michaelis - Lake Street Capital Markets Harvey Poppel - Poppel Operator Greetings. Welcome to Optim ...
OptimizeRx(OPRX) - 2021 Q4 - Annual Report
2022-02-28 21:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) | Nevada | 26-1265381 | | --- | --- | | (State or other ...
OptimizeRx(OPRX) - 2021 Q4 - Earnings Call Transcript
2022-02-25 03:12
OptimizeRx Corporation. (NASDAQ:OPRX) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Ed Stelmakh - Chief Financial Officer Stephen Silvestro - Chief Commercial Officer Andrew D’Silva - Senior Vice President of Corporate Finance Conference Call Participants Ryan Daniels - William Blair Sean Dodge - RBC Capital Markets Marc Wiesenberger - B. Riley Securities Eric Martinuzzi - Lake Street Harvey Poppel - Poptech Capital LLP Operator Go ...
OptimizeRx(OPRX) - 2021 Q3 - Earnings Call Transcript
2021-11-10 01:09
OptimizeRx Corporation (NASDAQ:OPRX) Q3 2021 Earnings Conference Call November 9, 2021 4:30 PM ET Company Participants William Febbo – Chief Executive Officer Ed Stelmakh – Chief Financial Officer Stephen Silvestro – Chief Commercial Officer Andrew D’Silva – Senior Vice President of Corporate Finance Conference Call Participants Jared Haase – William Blair Sean Dodge – RBC Capital Markets Eric Martinuzzi – Lake Street Marc Wiesenberger – B. Riley Securities Operator Good afternoon, and thank you for joining ...
OptimizeRx(OPRX) - 2021 Q3 - Quarterly Report
2021-11-09 21:12
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 or ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to __________ (State or other jurisd ...